Investment Highlights - Superficial Radiation Therapy (SRT) systems offer practitioners a quick ROI, potentially within 6-9 months, driven by a 50+% increase in reimbursement for the treatment course[7] - The company launched the "Fair Deal Agreement" recurring revenue program for the SRT-100 Vision (IG-SRT) using the Sentinel IT platform[7] - In 2023, the company's revenues reached $24.4 million with an EPS of $0.03 per share[7] - In the first half of 2024, revenues were $20 million, a 152% increase, with an EPS of $0.24, compared to a loss of $0.14 per share in the first half of 2023[7] - The company shipped 66 SRT systems in 2023 and 49 SRT systems in the first half of 2024[7] - As of June 30, 2024, the company has a strong balance sheet with $19.0 million in cash & equivalents, no debt, and receivables of $18.3 million[7] Technology and Market - 1 in 5 Americans will develop skin cancer in their lifetime[2] - Recurrence rates of keloids are up to 80% with surgery and other current treatment methods[25] - The company's installed base is currently at approximately 750 systems worldwide[59] Clinical Studies - A 2019 clinical multi-center study of 776 lesions showed a 98.9% cure rate after a 5-year retrospective study for skin cancer[32] - A 2018 clinical study of 151 lesions on lower extremities showed a 97.35% cure rate and a 5-year success rate of 97% for skin cancer[32] - A 2018 clinical study on keloid surgery followed with SRT for 297 lesions showed a 97% success rate[32]